23andMe Continuing GWAS into Disease Factors; Official 'Optimistic' Over FDA Talks | GenomeWeb

By Tony Fong

SAN FRANCISCO (GenomeWeb News) – Genetic testing firm 23andMe is continuing to leverage its database of patients using its tests to perform additional research, its senior director of research said Tuesday.

At the annual Burrill Personalized Medicine Meeting here, Joanna Mountain told audience members that the Mountain View, Calif., company is currently preparing studies in three areas.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.